The third tier, in full
Chapter 1 introduced three tiers for every value: population reference, functional optimal, and expected-enhanced. The first nine chapters built the first two tiers, panel by panel. This capstone is the third — what your bloodwork is supposed to do when you are on a protocol, and the hard lines that override everything else.
The single principle to hold: enhancement shifts where most markers are expected to sit, but it does not move the hard safety lines. A marker can be far outside the natural range as the expected, monitored consequence of a protocol — or it can be the one number that means stop, regardless of how good you feel. Telling those two apart is the whole skill.
What's expected — and not a problem
On a testosterone or androgen protocol, a set of shifts are the feedback loop working, not pathology:
- LH and FSH suppressed to near zero — expected on any exogenous androgen. This is not "secondary hypogonadism"; it's the axis responding correctly. It only becomes informative again during a restart.
- Total and free testosterone above the natural band — expected. Read the trough and symptoms, never a single peak.
- SHBG falling, especially on oral compounds — expected; it inflates free testosterone and shortens the apparent half-life of the picture.
- Estradiol rising roughly with dose and body fat — expected and protective. The goal is management, not eradication; crushing it with an aromatase inhibitor is the most common self-inflicted harm on this list.
- Hematocrit and hemoglobin climbing — expected from stimulated red-cell production.
- IGF-1 climbing toward or above the upper age band on GH-secretagogue protocols — expected; that's the point.
- Glucose and fasting insulin drifting up on GH-class protocols — expected, because growth hormone antagonizes insulin.
- Lipids shifting on oral compounds — HDL down, ApoB up, within weeks — expected.
None of these, on their own, is a reason to panic. They are the dials you set, reading where you set them.
The red flags that override "but I'm enhanced"
These get attention and usually a dose or compound reassessment, no matter how good the rest of the picture looks:
- Hematocrit above ~54% (or a fast climb through 52%) — the hard line. Raised blood viscosity and thrombotic risk; read it on a hydrated draw, because dehydration alone can inflate it. This is the marker that the rationalization "but my testosterone is perfect" exists to defeat.
- Sustained high ApoB / collapsed HDL that doesn't recover off cycle — the real cardiovascular cost of oral compounds, not an acceptable price.
- Climbing liver enzymes with a rising GGT or bilirubin, or any liver symptoms — the signal that an oral is doing genuine hepatobiliary damage, not just leaking muscle enzymes.
- Genuine eGFR decline confirmed on cystatin C — not the creatinine artifact, the real thing.
- Symptomatic estradiol at either extreme, or prolactin-driven sexual dysfunction on 19-nor compounds.
- Fasting insulin and HOMA-IR climbing on GH-class protocols — the metabolic cost of pushing the GH axis.
A good number on one marker never explains away a dangerous number on another. High testosterone with a hematocrit of 56% is not a win; it's a hematocrit of 56%.
A monitoring cadence that matches how the markers move
A practical baseline that mirrors the speed each safety marker moves: a full panel before starting, a follow-up at ~8 weeks into any new protocol or dose change — early enough to catch hematocrit, lipids, and liver moving — then every 3 months for the hematocrit / lipid / liver / IGF-1 safety cluster while a protocol is ongoing. The slower markers (Lp(a), thyroid antibodies) ride their usual long cadence. The faster a compound moves a marker, the tighter the retest interval on it.
The whole course in one sentence
Read every value in three tiers, act on the leading markers before the lagging ones break, confirm anything surprising on a clean second draw and the right assay — and never let enhancement talk you past a hard safety line.
Educational content, not individual medical advice.